Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET
Company Participants
Ryan Crowe - SVP, IR and Strategic Analysis
Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO
George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer
Marion McCourt - EVP, Commercial
Chris Fenimore - SVP, Finance and CFO
Conference Call Participants
Taylor Hanley - JPMorgan
Tyler Van Buren - TD Cowen
Brian Abrahams - RBC Capital Markets
Carter Gould - Barclays
Terence Flynn - Morgan Stanley
Christopher Raymond - Piper Sandler
Salveen Richter - Goldman Sachs
Mohit Bansal - Wells Fargo
Evan Seigerman - BMO Capital Markets
David Risinger - Leerink Partners
William Pickering - Bernstein
Cory Kasimov - Evercore ISI
Operator
Good morning and welcome to the Regeneron Pharmaceuticals' Third Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call. At this time all participants are on a listen-only mode.
Later we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.
Ryan Crowe
Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our third quarter 2024 earnings conference call. An archive and transcript of this call will be available on the Regeneron investor relations website shortly after the call ends.
Joining me on today's call are Dr. Leonard Schleifer, board Co-Chair, Co-Founder, President, and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore, Senior Vice President and Chief Financial Officer.
After our prepared remarks, the remaining time will be available for your questions. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement, intellectual property, pending litigation and other proceedings, and competition.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30th, 2024, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise.